Skip to main content
OpenTrials
Completed

NCT Number: NCT02524496

Limited Access Protocol for the Use of Oral Cisapride

Due to the lack of other drugs to treat gastroparesis Janssen and FDA approved the compassionate use of cisapride to treat patients who had no other effective therapy. For this observational study, 3 patients who had already been prescribed cisapride by outside physicians, were followed to determine the effectiveness of cisapride on their gastric emtpying.

Completed

Looking for future studies?

Notify Me

Key information

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Clinical diagnosis of gastroparesis.

Exclusion criteria

  • No diagnosis of gastroparesis.

Treatment and study plan

Primary outcomes

  1. Improvement in gastric emptying via self-report

    Time frame: ten years

    Patients were asked at clinical appointments about problems and improvement with gastric emptying.

Sponsors and collaborators

Lead sponsor

Yale University

Other

Registry information

Official study title

Limited Access, Open-label, Compassionate Use of Cisapride in the Treatment of Gastroparesis

Important dates

Study start
2001
Primary completion
2011
Study completion
2011
First posted
Aug 14, 2015
Registry last updated
Aug 14, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.